Lecture, Conference Presentation
Extending Human Lifespan
- Addressing aging directly as a root cause of chronic disease offers higher impact than treating individual diseases like heart disease and cancer separately.
- Curing all cancer would increase the average US female lifespan only to 85 (a +4 year gain), while curing all heart disease would raise it to 86 (a +5 year gain).
- Targeting aging directly could extend the average US female lifespan to 113, adding 30 years of healthy life.
- Current average lifespan is 81 years, whereas the average healthspan (onset of first chronic age-related disease) is only 62.
- Mice have reproducibly lived 20–30% longer in laboratory settings via aging interventions.
- Approximately 1% of the NIH's $37 billion annual research budget is allocated to basic mechanisms of aging.
- The field of aging research shifted from skepticism to prominence after 1993, when Cynthia Kenyon doubled the lifespan of C. elegans by deleting a single gene.
- Over the following decade, researchers identified several hundred genetic modifications that influence lifespan in invertebrates like yeast, flies, and worms.
- Rapamycin, an immunosuppressant derived from Easter Island bacteria, was found in a 2009 study to boost mouse lifespan by 14% when administered starting in middle age.
- Rapamycin has transitioned from mouse models to human trials via Restore Bio, with Phase 2b data showing a 30% reduction in respiratory infections due to improved immunosenescence.
- Senolytic therapies that delete senescent cells have demonstrated the potential to boost lifespan by up to 30% and significantly improve healthspan.
- Unity Biotechnology initiated a Phase 1 clinical trial for osteoarthritis earlier this year, marking a direct application of senolytic research in humans.
- Heterochronic parabiosis experiments (joining young and old mice) proved that young blood improves skeletal muscle, olfaction, and neurogenesis in old animals.
- BioAge is utilizing genomics and AI to identify specific circulating blood factors associated with longevity, including a protein that correlates with lower frailty and disease protection.
- Studies of exceptional human longevity, such as supercentenarian Leila Denmark who lived to 114, aim to identify genetic factors that modulate lifespan.
- Electronic health record mining led to the discovery that metformin, a diabetes drug, is associated with reduced cancer risk and increased longevity in diabetic patients.
- Three distinct therapeutic classes targeting aging—senolytics, rapamycin analogs, and metformin—are currently in clinical trials, potentially adding 10 to 20 years of healthy lifespan.
- There is no known hard biological limit to human lifespan, as evidenced by bowhead whales living over 200 years and bristlecone pines living over 5,000 years.